放射外科在MD安德森肿瘤中心的实践及进展

非小细胞肺癌（NSCLC）是我国最常见的恶性肿瘤之一。立体放射外科（SABR），也称立体定向放疗（SBRT），是一种无创性治疗，在现代精确的影像引导技术下给予局部肿瘤以高剂量、低分割的放射治疗，可获得超过90%的肿瘤局部控制率，已成为不可切除早期NSCLC的标准治疗，也是可手术早期NSCLC的治疗选择之一。美国德州大学MD安德森肿瘤中心（MDACC）作为全美肿瘤治疗排名第一的机构，对NSCLC的放射治疗进行了一系列颇具影响力的SABR临床试验和研究，促进了SABR在早期和晚期NSCLC中的应用。本文将MDACC对SABR的临床应用、研究结果和进展做一总结。

Practice and progress of stereotactic ablative radiotherapy in MD Anderson Cancer Center

Image-guided stereotactic ablative radiotherapy (SABR, also known as stereotactic body radiotherapy) is a non-invasive treatment by delivering ablative doses of radiation over one to ten fractions to tumors, and it achieves local control in excess of 90%. SABR has become a standard treatment for medically inoperable and an option for operable clinical early-stage non-small-cell lung cancer (NSCLC). The university of Texas MD Anderson Cancer Center (MDACC), as a top institute of cancer research and treatment worldwide, has conducted a series of influential SABR clinical trials and researches. The results have greatly promoted the application of SABR in early- and advanced-stage NSCLC. Here we summarize the clinical application, study progresses and findings of SABR for NSCLC in MDACC.